Delivering Healthcare With Fewer People
Healthcare is experiencing yet another crisis – one of many that have unfolded over the...
Abecma – Multiple Myeloma – MAR Display Banners HCP Wallboard Extension – 623660
Second-Line Therapies Continue to Evolve
Multiple myeloma (MM) treatment has evolved significantly since 2000, fueled by the approval of new agents as well as the precision medicine movement that is the mantra of clinical medicine, regardless of disease. Although there...
High Natural Killer Count Is Predictor of MRD-Negativity
For patients with multiple myeloma (MM) who are treated with autologous stem cell transplantation (ASCT), high absolute natural killer (NK) cell counts 2 to 3 months after ASCT are an independent predictor for minimal residual...
Fall Risk-Increasing Drug Use High in Older Adults With MM
The frequency of fall riskincreasing drug (FRID) use is high in older adults with multiple myeloma (MM) and is positively associated with polypharmacy, according to a study published in the Journal of Geriatric Oncology. Adriano...
